{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:52:11Z","timestamp":1791881531268,"version":"4.3.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004224","name":"Peter MacCallum Cancer Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004224","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["APP1175929"],"award-info":[{"award-number":["APP1175929"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jaad.2025.11.080","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T04:31:10Z","timestamp":1764390670000},"page":"1151-1157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Extended follow-up outcomes of patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab on EMPOWER-CSCC-1: A retrospective cohort study"],"prefix":"10.1016","volume":"94","author":[{"given":"Catherine","family":"Bennett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke S.","family":"McLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette M.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Bressel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Guminski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett G.M.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha E.","family":"Bowyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Rischin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2025.11.080_bib1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jdin.2020.10.013","article-title":"The global burden of skin cancer: a longitudinal analysis from the Global Burden of Disease Study, 1990-2017","volume":"2","author":"Urban","year":"2021","journal-title":"JAAD Int"},{"issue":"1","key":"10.1016\/j.jaad.2025.11.080_bib2","doi-asserted-by":"crossref","DOI":"10.17061\/phrp3212203","article-title":"Keratinocyte cancer incidence in Australia: a review of population-based incidence trends and estimates of lifetime risk","volume":"32","author":"Olsen","year":"2022","journal-title":"Public Health Res Pract"},{"issue":"4","key":"10.1016\/j.jaad.2025.11.080_bib3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2025.11.080_bib4","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","article-title":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial","volume":"21","author":"Migden","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2025.11.080_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000775","article-title":"Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing","volume":"8","author":"Rischin","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.jaad.2025.11.080_bib6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jaad.2024.06.108","article-title":"A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6","volume":"92","author":"Hughes","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"28","key":"10.1016\/j.jaad.2025.11.080_bib7","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-year overall survival for patients with advanced non\u2012small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study","volume":"37","author":"Garon","year":"2019","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jaad.2025.11.080_bib8","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.21.02885","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score \u2265 1% in the KEYNOTE-042 study","volume":"41","author":"de Castro","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2025.11.080_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2025.11.080_bib10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap) \u2013 a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"10","key":"10.1016\/j.jaad.2025.11.080_bib11","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.annonc.2021.07.008","article-title":"Pembrolizumab for locally advanced and recurrent\/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial","volume":"32","author":"Hughes","year":"2021","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.jaad.2025.11.080_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002757","article-title":"Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis","volume":"9","author":"Rischin","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.jaad.2025.11.080_bib13","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.mayocp.2017.02.015","article-title":"Incidence and trends of basal cell carcinoma and cutaneous squamous cell carcinoma: a population-based study in Olmsted County, Minnesota, 2000 to 2010","volume":"92","author":"Muzic","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jaad.2025.11.080_bib14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2023.01.017","article-title":"Incidence, mortality and trends of cutaneous squamous cell carcinoma in Germany, the Netherlands, and Scotland","volume":"183","author":"Keim","year":"2023","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.jaad.2025.11.080_bib15","doi-asserted-by":"crossref","first-page":"339","DOI":"10.5694\/mja17.00284","article-title":"The incidence and multiplicity rates of keratinocyte cancers in Australia","volume":"207","author":"Pandeya","year":"2017","journal-title":"Med J Aust"},{"issue":"15_suppl","key":"10.1016\/j.jaad.2025.11.080_bib16","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS9596","article-title":"CARSKIN: pembrolizumab as first line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC)","volume":"35","author":"Maubec","year":"2017","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.jaad.2025.11.080_bib17","doi-asserted-by":"crossref","first-page":"9554","DOI":"10.1200\/JCO.2024.42.16_suppl.9554","article-title":"Pembrolizumab (pembro) for locally advanced (LA) or recurrent\/metastatic (R\/M) cutaneous squamous cell carcinoma (cSCC): long-term results of the phase 2 KEYNOTE-629 study","volume":"42","author":"Mu\u00f1oz Couselo","year":"2024","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.jaad.2025.11.080_bib18","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1200\/JCO.22.01599","article-title":"Seven-year follow-up of the phase III KEYNOTE-006 study: pembrolizumab versus ipilimumab in advanced melanoma","volume":"41","author":"Robert","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.jaad.2025.11.080_bib19","doi-asserted-by":"crossref","first-page":"9520","DOI":"10.1200\/JCO.2022.40.16_suppl.9520","article-title":"Immunotherapy followed by cetuximab in locally advanced\/metastatic (LA\/M) cutaneous squamous cell carcinomas (cSCC): The I-TACKLE trial","volume":"40","author":"Bossi","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2025.11.080_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcskn.2024.100240","article-title":"Phase 2 study of intratumoral vidutolimod in combination with intravenous cemiplimab in patients with selected advanced cancer or metastatic cancer: trial in progress","volume":"2","author":"Bhatia","year":"2024","journal-title":"EJC Skin Cancer"},{"issue":"5_suppl","key":"10.1016\/j.jaad.2025.11.080_bib21","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.5_suppl.TPS219","article-title":"A phase 2 study of talimogene laherparepvec followed by talimogene laherparepvec + nivolumab in refractory T cell and NK cell lymphomas, cutaneous squamous cell carcinoma, Merkel cell carcinoma, and other rare skin tumors (NCI #10057)","volume":"36","author":"Silk","year":"2018","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.jaad.2025.11.080_bib22","doi-asserted-by":"crossref","first-page":"9561","DOI":"10.1200\/JCO.2022.40.16_suppl.9561","article-title":"A phase 1b\/2a study of safety and efficacy of NT-I7 in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1\/PD-L1 na\u00efve or relapsed\/refractory (R\/R) high-risk skin cancers: the phase 1b report","volume":"40","author":"Gastman","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.jaad.2025.11.080_bib23","doi-asserted-by":"crossref","first-page":"9534","DOI":"10.1200\/JCO.2023.41.16_suppl.9534","article-title":"Phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant Merkel cell carcinoma and cutaneous squamous cell carcinoma","volume":"41","author":"Brohl","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225032931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225032931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:26:54Z","timestamp":1791880014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225032931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0190962225032931"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.11.080","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extended follow-up outcomes of patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab on EMPOWER-CSCC-1: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.11.080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}